This study deals with the role of the stone matrix substance in formation of urinary stones. A series of coagulation experiments were conducted by determining the sedimentation rate of calcium carbonate suspension with respect to the following substances: sodium alginate, stone matrix substance, bovine albumin and chondroitin sulfate C, these were each added to a separate fine particle suspension of calcium carbonate. Changes in ξ-potential of the suspension particles after addition of the above materials were determined microscopically using Usui’s method. The results obtained in this study indicate that sodium alginate, the matrix substance, bovine albumin and chondroitin sulfate C act on the suspension particles, and as a result, coagulation is produced by a decrease of the ξ-potential of the particles. Application of kinetic energy to the coagulate caused by sodium alginate resulted in the formation of a solid. From these results it is considered that the matrix substance is not incorporated by accident in urinary stones, but it participates in the formation of them.

Keywords:
Urinary stone, Matrix substance, Mucosubstance, ξ-Potential, Sedimentation rate
This content is only available via PDF.
© 1976 S. Karger AG, Basel
1976
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.